News Search Results
Sep 02, 2026, 10:30 ET Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™
including monoclonal antibodies, fusion proteins, insulin and other recombinant proteins, with commercial portfolios spanning oncology, immunology, ophthalmology, endocrinology, and hematology. The competitive landscape is shaped by differences in portfolio breadth, regulatory approvals, manufacturing scale,
More news about: MarketsandMarkets
Sep 02, 2026, 07:00 ET Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
therapy, mRNA/LNP, siRNA, and small molecules, with a 12-project clinical-stage pipeline across anti-infectives, oncology, regenerative medicine, ophthalmology, otology, and medical aesthetics. More information is available at
More news about: Raziel Therapeutics; Fosun Pharma
Sep 02, 2026, 06:00 ET NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients'
More news about: NovaGo Therapeutics
Sep 02, 2026, 06:00 ET NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients'
More news about: NovaGo Therapeutics
Sep 01, 2026, 12:15 ET MatrixCare Becomes an Independent Company, Names Jonathan Lujan Chief Executive Officer
Chief Executive Officer of Sight Growth Partners, where he led the company's operational transformation and growth into one of the nation's largest ophthalmology management organizations. Previously, he served as Vice President and General Manager of Lifeline Vascular Care at DaVita and held multiple executive
More news about: MatrixCare
Sep 01, 2026, 10:30 ET Clear Aligners Market worth $11.04 billion by 2031 - Exclusive Report by MarketsandMarkets™
(Aluminum Oxide, Carbon), Polymer (Polyethylene, Polyester), Natural (Hyaluronic acid, Collagen, Gelatin)], Application (Orthopedic, Dental, CVD, Ophthalmology) - Global Forecast to 2030About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management
More news about: MarketsandMarkets
Sep 01, 2026, 07:30 ET Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Sep 01, 2026, 05:30 ET Exonate Becomes Foventa Therapeutics
eyes.CAMBRIDGE, England, Sept. 1, 2026 /PRNewswire/ -- Exonate Limited, a clinical-stage ophthalmology company, today announced that it has changed its name to Foventa Therapeutics. The new identity marks the company's transition from the science-led
More news about: Foventa Therapeutics
Sep 01, 2026, 04:49 ET Alcon's Clareon Monofocal IOL Receives EUMDR Certification Through TÜV SÜD
Hull J, Dhariwal M. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/s40123-023-00657-5 Clareon Vivity Directions for Use. Kohnen T, et al. Clin Ophthalmol.
More news about: Alcon
Aug 31, 2026, 18:00 ET Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Aug 31, 2026, 09:00 ET GT Independence Strengthens Leadership Team: Appoints Chris Karkenny as CEO
Independence from NVISION Eye Centers, where he served as CEO since 2018 and led the organization to become one of the nation's fastest-growing ophthalmology companies. His leadership experience in managing high-growth environments spans more than 25 years. Karkenny's experience has been focused primarily
More news about: GT Independence
Aug 28, 2026, 10:30 ET Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
focus on nine major disease areas: oncology, metabolic diseases, autoimmune diseases, neurology, cardiovascular diseases, infectious diseases, ophthalmology, aging-related diseases, and pet healthcare.Building on innovative molecular foundations, Clicklinks supports a wide range of therapeutic
More news about: Sanyou Bio
Aug 28, 2026, 08:03 ET Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
Pharmaceuticals, Inc. (TWSE: 6838) is a Taiwan-based biopharmaceutical company focused on the development and commercialization of novel therapeutics in ophthalmology and oncology. The company leverages its proprietary APNT® nanoparticle formulation platform to optimize drug solubility and bioavailability.
More news about: Formosa Pharmaceuticals Inc.,
Aug 27, 2026, 16:40 ET SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
Pharma looked to expand its footprint as it plans to scale up for commercialization of its innovative sustained drug delivery system and advance its ophthalmology pipeline."This is a special moment for SpyGlass," said Patrick Mooney, CEO of SpyGlass Pharma. "Our roots have always been in Orange County,
More news about: City of Irvine and SpyGlass Pharma
Aug 27, 2026, 11:03 ET Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension
glaucoma or ocular hypertension," said Joe Barna, CPA, Chief Executive Officer and President of KPA. "We're proud to bring Kowa's decades of global ophthalmology experience to the U.S. eye care community, and we look forward to working with the FDA throughout the review process."K-911 is an investigational,
More news about: Kowa Pharmaceuticals America, Inc.
Aug 27, 2026, 09:00 ET ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS
[email protected] for the press:Frank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Aug 27, 2026, 09:00 ET ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS
[email protected] for the press:Frank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Aug 26, 2026, 14:52 ET Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche
Aug 26, 2026, 10:49 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.For more information, visit: Piramal
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:45 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.For more information, visit: Piramal
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:00 ET Prevent Blindness Declares September as Sports Eye Safety Month to Raise Awareness, Provide Education to Help Avoid Eye Injuries
American Academy of Ophthalmology (AAO) states that players more likely to sustain an eye injury with more severe consequences include those with myopia or those who have had
More news about: Prevent Blindness
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
EngineIn general biomedicine, Innovent has established a clear framework across four major chronic disease areas—metabolic, cardiovascular, ophthalmology and autoimmune—and this franchise has become another core pillar of Innovent.SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative
More news about: Innovent Biologics
Aug 24, 2026, 19:30 ET Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
company committed to turning innovative science into value for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Aug 24, 2026, 08:00 ET Avulux Granted FDA De Novo Authorization, Creating the First Lens Classification for Migraine-Associated Light Sensitivity
Neurodegeneration. 2017;6:26. doi:10.1186/s40035-017-0095-34 Brennan KC, Digre K. Shedding Light on Photophobia Journal of Neuro-Ophthalmology. 2012;32(1):68-81. doi:10.1097/WNO.0b013e31824745485 Onofri A, Pensato U, Rosignoli C, et al. Primary headache epidemiology
More news about: Avulux
Aug 24, 2026, 07:00 ET Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche Diagnostics